Establishment Labs Holdings Inc. - ESTA STOCK NEWS

Establishment Labs Holdings Inc. (NASDAQ: ESTA) presented interim data from its Motiva US IDE Study at The Aesthetic Meeting 2022 in San Diego. This includes two-year follow-up data for 451 primary augmentation patients, showing a 94.9% compliance rate. Notable findings include low complication rates, with capsular contracture at 0.5% and rupture at 0.3%. Dr. Caroline Glicksman emphasized the significance of these preliminary results, contributing to the clinical understanding of Motiva Implants. The Motiva device remains investigational and not yet FDA-approved for commercial use in the U.S.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in The Aesthetic Meeting 2022 from April 20-24 in San Diego, California. Dr. Caroline Glicksman will present an update on the Motiva US Core Clinical Study on April 21 at 3:50pm PT. The company will also host an event honoring Dr. Brian Kinney's contributions to plastic surgery and women's health. Established in 2010, Establishment Labs specializes in breast aesthetics and reconstruction, delivering approximately 2.0 million Motiva Implants in over 80 countries.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, announced that CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 PM Eastern Time. A live webcast of the presentation can be accessed on the Establishment Labs investor relations website, with an archived version available afterward. The company specializes in breast aesthetics, offering Motiva Implants® and related products that have been delivered to over 80 countries.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported fourth-quarter 2021 revenue of $35.3 million, up 31% year-over-year, achieving a new quarterly record. The full-year revenue totaled $126.7 million, a 50% increase. Fourth-quarter gross profit was 68.6% of revenue, significantly higher than 54.3%% in 2020. For 2022, the company projects revenue of $155 million to $165 million, reflecting a 22% to 30% growth. However, operating expenses increased by 48.2% to $33.6 million.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has achieved a significant milestone by surpassing two million Motiva Implants in the market. This achievement reflects a steady growth trajectory, with the company delivering one million implants in the first seven years and doubling that in just two years. The implants maintain an impressive less than 1% clinical complication rate, showcasing their safety and effectiveness. Operating in over 80 countries, Establishment Labs is committed to innovation in breast aesthetics and reconstruction, aiming to raise standards in women's health.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ending December 31, 2021, on March 1, 2022, before market opens. The company will host a conference call at 8:30 am ET the same day to discuss these results. Established in 2010, the company focuses on women’s health, particularly breast aesthetics and reconstruction, offering innovative silicone gel-filled Motiva Implants^®. Over 2 million of these implants have been distributed across 80 countries, emphasizing its global presence and commitment to advanced healthcare solutions.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary unaudited revenue for Q4 2021 expected between $35.0 million and $35.5 million, signifying a growth of 30% to 32% year-over-year. For the fiscal year 2021, the company anticipates revenue of $126.4 million to $126.9 million, reflecting a growth of 49% to 50% compared to 2020. The company will share its complete financial results on March 1, 2022.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global leader in women's health technology, has announced that CEO Juan José Chacón-Quirós will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative Motiva Implants with over 1.8 million units delivered since 2010 across 80 countries.

Establishment Labs (NASDAQ: ESTA) has appointed Raj Denhoy as Chief Financial Officer, effective immediately. Denhoy, who joined the company in February 2021 and served as Interim CFO since August, has extensive experience in medical device research. CEO Juan José Chacón-Quirós highlighted Denhoy's understanding of the business and industry vision. Denhoy expressed optimism about the company's potential to lead in breast aesthetics and reconstruction, emphasizing innovation and stakeholder value.